Lung Cancer Mutation Consortium

USA

The Lung Cancer Mutation Consortium (LCMC) is a collaborative network of leading cancer centers and researchers focused on the comprehensive molecular profiling of lung cancer tumors to identify genetic mutations that drive the disease. By pooling data and expertise from multiple institutions, the LCMC enables large-scale genomic analysis, which guides personalized treatment strategies tailored to the unique genetic makeup of each patient’s tumor. This network plays a critical role in advancing precision medicine in lung cancer by facilitating the development and application of targeted therapies, improving patient outcomes, and accelerating research into the genetic underpinnings of lung cancer. Through its coordinated efforts, the LCMC fosters collaboration, data sharing, and innovation across the lung cancer research community.